Base de dados : MEDLINE
Pesquisa : D27.505.696.282 [Categoria DeCS]
Referências encontradas : 16217 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1622 ir para página                         

  1 / 16217 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29215336
[Au] Autor:Sayilan Özgün G; Özgün E; Tabakçioglu K; Süer Gökmen S; Eskiocak S; Çakir E
[Ad] Endereço:Department of Medical Biochemistry, Trakya University School of Medicine, Edirne, Turkey.
[Ti] Título:Caffeine Increases Apolipoprotein A-1 and Paraoxonase-1 but not Paraoxonase-3 Protein Levels in Human-Derived Liver (HepG2) Cells.
[So] Source:Balkan Med J;34(6):534-539, 2017 12 01.
[Is] ISSN:2146-3131
[Cp] País de publicação:Turkey
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Apolipoprotein A-1, paraoxonase-1 and paraoxonase-3 are antioxidant and anti-atherosclerotic structural high-density lipoprotein proteins that are mainly synthesized by the liver. No study has ever been performed to specifically examine the effects of caffeine on paraoxonase enzymes and on liver apolipoprotein A-1 protein levels. AIMS: To investigate the dose-dependent effects of caffeine on liver apolipoprotein A-1, paraoxonase-1 and paraoxonase-3 protein levels. STUDY DESIGN: experimental study. METHODS: HepG2 cells were incubated with 0 (control), 10, 50 and 200 µM of caffeine for 24 hours. Cell viability was evaluated by 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. Apolipoprotein A-1, paraoxonase-1 and paraoxonase-3 protein levels were measured by western blotting. RESULTS: We observed a significant increase on apolipoprotein A-1 and paraoxonase-1 protein levels in the cells incubated with 50 µM of caffeine and a significant increase on paraoxonase-1 protein level in the cells incubated with 200 µM of caffeine. CONCLUSION: Our study showed that caffeine does not change paraoxonase-3 protein level, but the higher doses used in our study do cause an increase in both apolipoprotein A-1 and paraoxonase-1 protein levels in liver cells.
[Mh] Termos MeSH primário: Apolipoproteína A-I/efeitos dos fármacos
Arildialquilfosfatase/efeitos dos fármacos
Cafeína/farmacologia
Estimulantes do Sistema Nervoso Central/farmacologia
Células Hep G2/efeitos dos fármacos
Fígado/patologia
[Mh] Termos MeSH secundário: Análise de Variância
Western Blotting
Sobrevivência Celular/efeitos dos fármacos
Relação Dose-Resposta a Droga
Seres Humanos
Técnicas In Vitro
Lipoproteínas HDL
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Apolipoprotein A-I); 0 (Central Nervous System Stimulants); 0 (Lipoproteins, HDL); 3G6A5W338E (Caffeine); EC 3.1.8.1 (Aryldialkylphosphatase); EC 3.1.8.1 (PON1 protein, human); EC 3.1.8.1 (PON3 protein, human)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.4274/balkanmedj.2016.1217


  2 / 16217 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465560
[Au] Autor:Xue X; Song Y; Yu X; Fan Q; Tang J; Chen X
[Ad] Endereço:Department of Substance Abuse, Qingdao Mental Health Center, Qingdao.
[Ti] Título:Olanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants: A randomized controlled trial.
[So] Source:Medicine (Baltimore);97(8):e9786, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This study aimed to compare olanzapine and haloperidol efficacies in the treatment of acute psychiatric symptoms due to amphetamine-type stimulants (ATSs). METHODS: The Zelen II design method was used; 124 patients with acute mental disorders due to amphetamine were randomly divided into olanzapine group (n = 63) and haloperidol group (n = 61). Then, a 4-week open-label medical therapy was performed. Clinical Global Impression Scale Item 2 was employed to evaluate the onset time; meanwhile, Brief Psychiatric Rating Scale (BPRS) was used at baseline and at posttreatment weeks 1, 2, and 4. Moreover, adverse reactions during the treatment were recorded. RESULTS: Onset time in the olanzapine group was significantly earlier than in the haloperidol group; BPRS scores in the olanzapine group were significantly lower than haloperidol group values at 1 and 2 weeks of treatment. The overall effective rates had no statistically significant difference. CONCLUSION: Short-term olanzapine and haloperidol treatments had equivalent efficacies in the treatment of acute symptoms of mental disorders due to ATSs; however, olanzapine administration resulted in relatively earlier disease onset, with less adverse reactions.
[Mh] Termos MeSH primário: Transtornos Relacionados ao Uso de Anfetaminas/tratamento farmacológico
Antipsicóticos/administração & dosagem
Benzodiazepinas/administração & dosagem
Haloperidol/administração & dosagem
Transtornos Mentais/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Anfetamina/efeitos adversos
Transtornos Relacionados ao Uso de Anfetaminas/psicologia
Escalas de Graduação Psiquiátrica Breve
Estimulantes do Sistema Nervoso Central/efeitos adversos
Feminino
Seres Humanos
Masculino
Transtornos Mentais/induzido quimicamente
Projetos de Pesquisa
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Central Nervous System Stimulants); 12794-10-4 (Benzodiazepines); CK833KGX7E (Amphetamine); J6292F8L3D (Haloperidol); N7U69T4SZR (olanzapine)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009786


  3 / 16217 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29386447
[Au] Autor:Mori T; Sawaguchi T
[Ad] Endereço:Department of Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences.
[Ti] Título:[Underlying Mechanisms of Methamphetamine-Induced Self-Injurious Behavior and Lethal Effects in Mice].
[So] Source:Nihon Eiseigaku Zasshi;73(1):51-56, 2018.
[Is] ISSN:1882-6482
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Relatively high doses of psychostimulants induce neurotoxicity on the dopaminergic system and self-injurious behavior (SIB) in rodents. However the underlying neuronal mechanisms of SIB remains unclear. Dopamine receptor antagonists, N-methyl-D-aspartic acid (NMDA) receptor antagonists, Nitric Oxide Synthase (NOS) inhibitors and free radical scavengers significantly attenuate methamphetamine-induced SIB. These findings indicate that activation of dopamine as well as NMDA receptors followed by radical formation and oxidative stress, especially when mediated by NOS activation, is associated with methamphetamine-induced SIB. On the other hand, an increase in the incidence of polydrug abuse is a major problem worldwide. Coadministered methamphetamine and morphine induced lethality in more than 80% in mice, accompanied by an increase in the number of poly (ADP-ribose) polymerase (PARP)-immunoreactive cells in the heart, kidney and liver. The lethal effect and the increase in the incidence of rupture or PARP-immunoreactive cells induced by the coadministration of methamphetamine and morphine were significantly attenuated by pretreatment with a phospholipase A2 inhibitor or a radical scavenger, or by cooling of body from 30 to 90 min after drug administration. These results suggest that free radicals play an important role in the increased lethality induced by the coadministration of methamphetamine and morphine. Therefore, free radical scavengers and cooling are beneficial for preventing death that is induced by the coadministration of methamphetamine and morphine. These findings may help us better understand for masochistic behavior, which is a clinical phenomenon on SIB, as well as polydrug-abuse-induced acute toxicity.
[Mh] Termos MeSH primário: Estimulantes do Sistema Nervoso Central/efeitos adversos
Estimulantes do Sistema Nervoso Central/toxicidade
Metanfetamina/efeitos adversos
Metanfetamina/toxicidade
Comportamento Autodestrutivo/induzido quimicamente
[Mh] Termos MeSH secundário: Animais
Antagonistas de Dopamina/farmacologia
Antagonistas de Dopamina/uso terapêutico
Neurônios Dopaminérgicos/efeitos dos fármacos
Relação Dose-Resposta a Droga
Interações Medicamentosas
Depuradores de Radicais Livres/farmacologia
Depuradores de Radicais Livres/uso terapêutico
Radicais Livres/efeitos adversos
Radicais Livres/toxicidade
Seres Humanos
Dose Letal Mediana
Metanfetamina/administração & dosagem
Morfina/administração & dosagem
Morfina/efeitos adversos
Morfina/toxicidade
Receptores de N-Metil-D-Aspartato/antagonistas & inibidores
Comportamento Autodestrutivo/etiologia
Transtornos Relacionados ao Uso de Substâncias
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 0 (Dopamine Antagonists); 0 (Free Radical Scavengers); 0 (Free Radicals); 0 (Receptors, N-Methyl-D-Aspartate); 44RAL3456C (Methamphetamine); 76I7G6D29C (Morphine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1265/jjh.73.51


  4 / 16217 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29370197
[Au] Autor:Lauritzen G; Nordfjærn T
[Ad] Endereço:Department of Drug Policy, Norwegian Institute of Public Health, Oslo, Norway.
[Ti] Título:Changes in opiate and stimulant use through 10 years: The role of contextual factors, mental health disorders and psychosocial factors in a prospective SUD treatment cohort study.
[So] Source:PLoS One;13(1):e0190381, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:AIM: To examine temporal changes in opiate and stimulant use among patients in substance abuse treatment over a ten-year observation period and to explore the role of contextual factors, mental health disorders and psychosocial factors on these changes. METHODS: A cohort of 481 patients was prospectively interviewed at admission to treatment and after 1, 2, 7 and 10 years. The sample was recruited from 20 facilities in the Greater Oslo region, Norway. RESULTS: The majority of patients were poly-drug users and 80% had used both opiates and stimulants the last 30 days prior to treatment admission. Last-month use of heroin, other opiates, cocaine and amphetamines declined from 80% to 34% at the end of the observation period. The most substantial reduction was observed between baseline and one-year follow-up. Use of heroin decreased the most from 62% to 16% after 10 years (a reduction of 74%), and the reduction continued from one-year follow-up throughout the observation period. The most important multivariate risk factors for sustained use of these drugs were male gender, having one or both biological parents with severe alcohol or drug problems, having an antisocial personality disorder, and living together with a person who abuses alcohol or drugs. Employment was associated with reduced risk of drug use at 7-year follow-up. CONCLUSIONS: There was a substantial reduction in opiate and stimulant use from baseline to all follow-up assessments, most greatly for heroin. Findings regarding sustained use could suggest familial transmission and the challenges of preventive strategies and treatment efforts in an intergenerational context. Co-occurrence between drug abuse and mental health problems highlights the need of highly specialized competence in SUD treatment.
[Mh] Termos MeSH primário: Analgésicos Opioides/administração & dosagem
Estimulantes do Sistema Nervoso Central/administração & dosagem
Transtornos Mentais/complicações
Psicologia
Transtornos Relacionados ao Uso de Substâncias/complicações
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Masculino
Noruega
Estudos Prospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Central Nervous System Stimulants)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190381


  5 / 16217 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29258368
[Au] Autor:Ward K; Citrome L
[Ad] Endereço:a University of Michigan College of Pharmacy , Ann Arbor , MI , USA.
[Ti] Título:Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder.
[So] Source:Expert Opin Drug Metab Toxicol;14(2):229-238, 2018 Feb.
[Is] ISSN:1744-7607
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The indications for lisdexamfetamine (LDX), a central nervous system stimulant, were recently expanded to include treatment of moderate to severe binge eating disorder (BED). Areas covered: This review aims to describe the chemistry and pharmacology of LDX, as well as the clinical trials investigating the efficacy and safety of this medication for the management of BED. Expert opinion: LDX is the first medication with United States Food and Drug Administration approval for the treatment of BED. It is an inactive prodrug of d-amphetamine that extends the half-life of d-amphetamine to allow for once daily dosing. D-amphetamine acts primarily to increase the concentrations of synaptic dopamine and norepinephrine. Metabolism of LDX to d-amphetamine occurs when peptidases in red blood cells cleave the covalent bond between d-amphetamine and l-lysine. D-amphetamine is then further metabolized by CYP2D6. Excretion is primarily through renal mechanisms. In clinical trials, LDX demonstrated statistical and clinical superiority over placebo in reducing binge eating days per week at doses of 50 and 70 mg daily. Commonly reported side effects of LDX include dry mouth, insomnia, weight loss, and headache, and its use should be avoided in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia or coronary artery disease. As with all CNS stimulants, risk of abuse needs to be assessed prior to prescribing.
[Mh] Termos MeSH primário: Transtorno da Compulsão Alimentar/tratamento farmacológico
Estimulantes do Sistema Nervoso Central/administração & dosagem
Dimesilato de Lisdexanfetamina/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Transtorno da Compulsão Alimentar/fisiopatologia
Estimulantes do Sistema Nervoso Central/efeitos adversos
Estimulantes do Sistema Nervoso Central/farmacocinética
Esquema de Medicação
Meia-Vida
Seres Humanos
Dimesilato de Lisdexanfetamina/efeitos adversos
Dimesilato de Lisdexanfetamina/farmacocinética
Metildopa/metabolismo
Norepinefrina/metabolismo
Pró-Fármacos
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 0 (Prodrugs); 56LH93261Y (Methyldopa); SJT761GEGS (Lisdexamfetamine Dimesylate); X4W3ENH1CV (Norepinephrine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.1080/17425255.2018.1420163


  6 / 16217 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29250981
[Au] Autor:Evangelista E; Lopez R; Dauvilliers Y
[Ad] Endereço:a Centre National de Référence Narcolepsie Hypersomnies, Unité des Troubles du Sommeil, Service de Neurologie , Hôpital Gui-de-Chauliac Montpellier , Montpellier , France.
[Ti] Título:Update on treatment for idiopathic hypersomnia.
[So] Source:Expert Opin Investig Drugs;27(2):187-192, 2018 Feb.
[Is] ISSN:1744-7658
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Idiopathic hypersomnia (IH) is a poorly characterized orphan central disorder of hypersomnolence responsible for excessive daytime sleepiness (EDS), prolonged nighttime sleep and sleep inertia that often require long-term symptomatic stimulant medication. To date, no drug has currently the authorization for the treatment of IH patients worldwide. Areas covered: The authors reviewed data on pharmacological treatment of IH obtained from published literature (Medline/PubMed/Web of Science) and Clinicaltrial.gov database from 1997 to 2017. Most of data on treatment of IH derived from observational studies and case series with only three well-designed clinical trials available. Expert opinion: In two recent randomized, double-blind, placebo-controlled trials, modafinil improves EDS in IH. Most of other wakefulness-promoting agents labeled for narcolepsy have similar efficacy in cases series of IH patients. Pitolisant and sodium oxybate show promising results in two retrospective studies. The efficacy of γ-aminobutyric acid-A receptor antagonists on objective EDS needs to be clarified. All these medications are used off-label for the management of EDS in IH. Specific clinical instruments and objective tests are required in IH to better evaluate the severity of EDS and responsiveness to medications, but also prolonged sleep and sleep inertia, to optimize the whole management of IH patients.
[Mh] Termos MeSH primário: Estimulantes do Sistema Nervoso Central/uso terapêutico
Hipersonolência Idiopática/tratamento farmacológico
Promotores da Vigília/uso terapêutico
[Mh] Termos MeSH secundário: Aprovação de Drogas
Antagonistas de Receptores de GABA-A/uso terapêutico
Seres Humanos
Hipersonolência Idiopática/fisiopatologia
Uso Off-Label
Ensaios Clínicos Controlados Aleatórios como Assunto
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 0 (GABA-A Receptor Antagonists); 0 (Wakefulness-Promoting Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.1080/13543784.2018.1417385


  7 / 16217 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29339866
[Au] Autor:Wasserman RM; Stoner AM; Stern A; Holmbeck GN
[Ad] Endereço:Department of Pediatrics, Section of Psychology, Baylor College of Medicine, Houston, Texas.
[Ti] Título:ADHD and Attention Problems in Children With and Without Spina Bifida.
[So] Source:Top Spinal Cord Inj Rehabil;22(4):253-259, 2016.
[Is] ISSN:1945-5763
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To identify differences in the diagnosis and treatment of attention deficit/hyperactivity disorder (ADHD) between typically developing children and children with spina bifida. Sixty-eight children with spina bifida and 68 demographically matched, typically developing children participated in a larger, longitudinal study. Rates of maternal, paternal, and teacher reports of attention problems, as well as rates of maternal reports of ADHD diagnosis, diagnosing provider, pharmaceutical treatment, mental health treatment, and academic accommodations were obtained at 5 time points over a period of 8 years and were compared across groups. Children with spina bifida were more likely to have an ADHD diagnosis and attention problems. Attention problems and ADHD diagnoses were first reported at earlier time points for children with spina bifida than typically developing children. Among children with ADHD or attention problems, children with spina bifida were more likely to be treated with medication, but they were just as likely to use mental health services and receive resource services at school. Children with spina bifida were diagnosed with ADHD and identified as having attention problems more frequently and at an earlier age. This finding could be due to earlier symptom development, greater parental awareness, or more contact with providers. Among those with ADHD or attention problems, stimulant medication was more likely to be prescribed to children with spina bifida, despite research that suggests it may not be as beneficial for them. Further research on the effectiveness of ADHD pharmacological treatment for children with spina bifida is recommended.
[Mh] Termos MeSH primário: Transtorno do Deficit de Atenção com Hiperatividade/complicações
Disrafismo Espinal/complicações
[Mh] Termos MeSH secundário: Atenção
Estudos de Casos e Controles
Estimulantes do Sistema Nervoso Central
Criança
Feminino
Seres Humanos
Estudos Longitudinais
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Central Nervous System Stimulants)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.1310/sci2204-253


  8 / 16217 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449914
[Au] Autor:Kalil Neto F; Nunes ML
[Ad] Endereço:Division of Neurology, Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
[Ti] Título:Evaluation of sleep organization in patients with attention deficit hyperactivity disorder (ADHD) and ADHD as a comorbidity of epilepsy.
[So] Source:Sleep Med;33:91-96, 2017 May.
[Is] ISSN:1878-5506
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE/BACKGROUND: Epilepsy or attention deficit hyperactivity disorder (ADHD) can influence sleep organization in different ways. The aim of this study was to evaluate sleep organization in children and adolescents with ADHD and epilepsy, and to analyze the influence of methylphenidate. METHODS: This was an observational, cross-sectional study of children and adolescents with epilepsy, who were seizure free for at least three months, and were also diagnosed with ADHD. They were selected from the epilepsy and child neurology outpatient clinic of a university hospital in Brazil. After sample size calculation, patients were consecutively included into four different groups, with 21 patients each: epilepsy + ADHD using methylphenidate, epilepsy + ADHD not using methylphenidate, only ADHD, and a healthy control group. All participants were evaluated with the Sleep Disturbance Scale for Children (SDSC) and monitored with actigraphy for five nights/days. RESULTS: Actigraphic analysis showed a higher number of night awakenings in the epilepsy + ADHD groups; they were most prominent in the group without methylphenidate (p = 0.001). Parental reports demonstrated a higher risk for sleep disturbances in the epilepsy + ADHD without methylphenidate and the ADHD groups (p < 0.001). CONCLUSION: Primary ADHD as a comorbidity of epilepsy impairs sleep organization in children, and the use of short-acting methylphenidate seems to improve it. Both objective (actigraphic) and subjective (SDSC) measures showed significant sleep alterations between primary ADHD and ADHD as a comorbidity of epilepsy; this was most prominent in the group without methylphenidate.
[Mh] Termos MeSH primário: Transtorno do Deficit de Atenção com Hiperatividade/complicações
Epilepsia/complicações
Metilfenidato/efeitos adversos
Transtornos do Sono-Vigília/tratamento farmacológico
Sono/efeitos dos fármacos
[Mh] Termos MeSH secundário: Actigrafia/métodos
Adolescente
Transtorno do Deficit de Atenção com Hiperatividade/diagnóstico
Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico
Transtorno do Deficit de Atenção com Hiperatividade/epidemiologia
Brasil/epidemiologia
Estimulantes do Sistema Nervoso Central/efeitos adversos
Estimulantes do Sistema Nervoso Central/farmacologia
Criança
Comorbidade
Estudos Transversais
Epilepsia/diagnóstico
Epilepsia/tratamento farmacológico
Epilepsia/epidemiologia
Feminino
Seres Humanos
Masculino
Metilfenidato/farmacologia
Transtornos do Sono-Vigília/epidemiologia
Transtornos do Sono-Vigília/fisiopatologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 207ZZ9QZ49 (Methylphenidate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  9 / 16217 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27776672
[Au] Autor:Hellem TL
[Ad] Endereço:Montana State University College of Nursing, Missoula, MT 59812-7416, United States. Electronic address: tracy.hellem1@montana.edu.
[Ti] Título:A Review of Methamphetamine Dependence and Withdrawal Treatment: A Focus on Anxiety Outcomes.
[So] Source:J Subst Abuse Treat;71:16-22, 2016 12.
[Is] ISSN:1873-6483
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Rates of anxiety disorders among individuals who use methamphetamine are estimated to be as high as 30.2%. The presence of an anxiety disorder in methamphetamine users is associated with higher rates of relapse, non-adherence to treatment and poorer outcomes relative to methamphetamine users without an anxiety disorder. A review investigating current treatment options for methamphetamine dependence or withdrawal from methamphetamine was conducted using PubMed, CINAHL and PsycINFO. The focus of the review was trials that utilized an intervention and collected anxiety as an outcome measure. Seven studies were included in the review, and five of these studies examined a pharmacotherapy option, one studied a psychosocial intervention and one study investigated exercise as an intervention. Some of the pharmacotherapy studies and the study of exercise were associated with improvements in mood and/or a reduction in methamphetamine use. Concerns of sample size and measurement of anxiety were raised. Future well-designed research with large sample sizes is warranted to examine how to manage anxiety among methamphetamine users.
[Mh] Termos MeSH primário: Transtornos Relacionados ao Uso de Anfetaminas/terapia
Transtornos de Ansiedade
Estimulantes do Sistema Nervoso Central
Metanfetamina
Avaliação de Resultados (Cuidados de Saúde)
Síndrome de Abstinência a Substâncias/terapia
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Central Nervous System Stimulants); 44RAL3456C (Methamphetamine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  10 / 16217 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29245022
[Au] Autor:Zhang SX; Shoptaw S; Reback CJ; Yadav K; Nyamathi AM
[Ad] Endereço:San Diego State University, Department of Sociology, San Diego, CA, USA. Electronic address: szhang@mail.sdsu.edu.
[Ti] Título:Cost-effective way to reduce stimulant-abuse among gay/bisexual men and transgender women: a randomized clinical trial with a cost comparison.
[So] Source:Public Health;154:151-160, 2018 Jan.
[Is] ISSN:1476-5616
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: A randomized controlled study was conducted with 422 homeless, stimulant-using gay/bisexual (G/B) men and 29 transgender women (n = 451) to assess two community-based interventions to reduce substance abuse and improve health: (a) a nurse case-managed program combined with contingency management (NCM + CM) versus (b) standard education plus contingency management (SE + CM). STUDY DESIGN: Hypotheses tested included: a) completion of hepatitis A/B vaccination series; b) reduction in stimulant use; and c) reduction in number of sexual partners. METHODS: A deconstructive cost analysis approach was utilized to capture direct costs associated with the delivery of both interventions. Based on an analysis of activity logs and staff interviews, specific activities and the time required to complete each were analyzed as follows: a) NCM + CM only; b) SE + CM only; c) time to administer/record vaccines; and d) time to receive and record CM visits. Cost comparison of the interventions included only staffing costs and direct cash expenditures. RESULTS: The study outcomes showed significant over time reductions in all measures of drug use and multiple sex partners, compared to baseline, although no significant between-group differences were detected. Cost analysis favored the simpler SE + CM intervention over the more labor-intensive NCM + CM approach. Because of the high levels of staffing required for the NCM relative to SE, costs associated with it were significantly higher. CONCLUSIONS: Findings suggest that while both intervention strategies were equally effective in achieving desired health outcomes, the brief SE + CM appeared less expensive to deliver.
[Mh] Termos MeSH primário: Estimulantes do Sistema Nervoso Central/administração & dosagem
Análise Custo-Benefício
Promoção da Saúde/economia
Minorias Sexuais e de Gênero/psicologia
Transtornos Relacionados ao Uso de Substâncias/prevenção & controle
[Mh] Termos MeSH secundário: Adulto
Bissexualidade/psicologia
Bissexualidade/estatística & dados numéricos
Feminino
Promoção da Saúde/métodos
Pessoas em Situação de Rua/psicologia
Pessoas em Situação de Rua/estatística & dados numéricos
Homossexualidade Masculina/psicologia
Homossexualidade Masculina/estatística & dados numéricos
Seres Humanos
Masculino
Minorias Sexuais e de Gênero/estatística & dados numéricos
Pessoas Transgênero/psicologia
Pessoas Transgênero/estatística & dados numéricos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Central Nervous System Stimulants)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE



página 1 de 1622 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde